English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Since the introduction of modern non-steroidal antiinflammatory drugs (NSAIDs) with ibuprofen and indomethacin, numerous compounds have been synthesised and tested for the treatment of rheumatic diseases. Since long term therapy with NSAIDs is occasionally associated with serious side effects, e.g., large intestinal ulcers, bleeding, perforation, relapse of classic inflammatory bowel disease, or complications of diverticular disease (fistula and perforation) (Szabo et al. 1989, Bjarnason et al. 1993), the development of novel compounds with improved efficacy and less toxic effect is constantly desirable. Possible targets of

Synthesis and activity of 4-(2',4'-difluorobiphenylyl)-2-methylbutyric acid (deoxoflobufen) and its derivatives